Abstract
Patients aged 70 years and older accounted for 42% of all lung cancer deaths in Poland in 2005. Although the incidence of lung cancer in elderly people is growing in Poland, like in other developed countries, the standards of treatment for this subset of population are not well established. Prospective elderly-specific trials concerning curative treatment are lacking. The results from prospective trials including elderly participants show similar effectiveness as in younger population at the expense of higher toxicity. Selection bias may limit the ability to generalize results of clinical trials to the entire population of elderly people. Methods of curative treatment (surgery, radiotherapy, chemotherapy as adjuvant for non-small cell lung cancer and basic treatment for limited-stage small cell lung cancer) are discussed. Some treatment options and modifications of standard strategies which are particularly promising in elderly patients, as VADS surgery, stereotactic radiotherapy or abbreviated treatment for SCLC, are presented.